Rilotumumab
20120142
Phase 3 small_molecule terminated
Quick answer
Rilotumumab for Gastric Cancer is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Gastric Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated